Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
J-LANCELOT: Atopaxar in Japanese ACS Patients
NCT00619164Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Nov 2007
- Primary completion
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of atopaxar in acute coronary syndrome (ACS) (4 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Safety and Tolerability at 3 months. Started Nov 2007; status: completed.
02
Drugs
atopaxar
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT00619164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00619164.